UNSPSC 51202803: Sirolimus

This classification denotes a bcar2 gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W36ZG6FT64. European Medicines Agency schedules Rapamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10537MIG. Sirolimus generally arises in the molecular formula C51H79NO13.

The term SIROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) SIROLIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sirolimus under HS 29349990 and SITC 51579. As of Q4 2014, SIROLIMUS remains US FDA's Preferred Term for this commodity. Sirolimus bears US NLM identifiers UMLS ID C0072980 and NCI Concept Code C1212.

UNSPSC 51202803 Sirolimus is a Commodity code that nominally addresses a specific immunosuppressant pharmaceutical, but recent state and local solicitations show limited direct procurement activity under this code. The recent opportunities block contains four records, only one of which (the MMCAP generic pharmaceuticals RFP) relates to pharmaceutical sourcing at scale; the others address naloxone and drug deactivation systems, medical and first aid supplies for emergency response, and a Texas HHS market-intelligence inquiry into direct-to-manufacturer prescription programs. None of these solicitations explicitly names sirolimus or immunosuppressants as line items, suggesting the code may be underutilized or misaligned with actual state and local pharmaceutical procurement practice in the dataset. State and local buyers conducting pharmaceutical procurement appear to work through cooperative purchasing vehicles (MMCAP in Minnesota and Oregon), health agencies (Texas HHS), and individual jurisdictions (Seminole County, Florida; City of Tampa), but sirolimus-specific demand does not surface in the recent record.

The geographic spread in recent opportunities spans Minnesota and Oregon (cooperative), Texas (state HHS), and Florida (county), with activity concentrated in multi-state cooperative contracting for generic pharmaceuticals and OTC products rather than specialty-drug procurement by single jurisdiction. The Minnesota Multistate Cooperative Purchasing Alliance RFP (due March 26, 2026) seeking generic multi-source pharmaceuticals and OTC products through authorized wholesalers represents the closest match to pharmaceutical commodities, though it does not isolate sirolimus. The Texas HHS RFI (response deadline April 3, 2026) explores direct-to-manufacturer prescription fulfillment models, but targets the broader market-intelligence phase before formal procurement. No recent sirolimus-specific RFPs, IFBs, or RFQs appear in the source; pursuit under this code would require either monitoring for specialty pharmaceutical cooperative vehicles or direct outreach to state Medicaid or institutional buyer segments not reflected in the current activity block.